 If theres an asset class thats looking forward to 2022, its small- and mid-cap SMID biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more reasons for investors to monitor exchange traded funds, such as the ALPS Medical Breakthroughs ETF SBIO, beyond things cant get much worse sentiment. 